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In his review article [1], Professor van den Berg discusses
anti-cytokine therapy of RA and hypothesises that, in order
to prevent joint destruction, it is necessary to block IL-1 in
addition to TNF. The rationale for this hypothesis stems
largely from observations in experimental models of arthri-
tis in rodents. However, as he points out in the abstract,
the necessity arises “if elements of the models apply to
the arthritic process in RA patients”. This surely is the
central point, and the critical question is whether animal
models resemble the human disease process. This issue
has been extensively debated and even in the best-defined
models, such as collagen-induced arthritis in DBA/1 mice,
the aggressive, acute nature of the disease makes it unlike
human RA. The very lack of chronicity in experimental
models is a major limitation. Although these models and
cytokine transgenic mice, despite their drawbacks, have
been an invaluable tool to test hypotheses in vivo and to
further explore mechanisms in a real-life setting, they can
never fully mimic human RA.
Perhaps one of the best-studied models illustrating the
problem of extrapolation from animal models to human
disease is one in the huTNF transgenic mouse developed
by Kollias and colleagues a decade ago. Replacement
with 3¢UTR of b-globin of the normal regulatory untrans-
lated region in the TNF gene resulted in chronic arthritis in
the Tg 197 line; the development of this arthritis was
specifically blocked by antihuman, but not antimouse,
TNF-a antibodies [2]. However, what is clearly important
(even central) to the development of arthritis in these mice
is the fact that the trans gene is expressed as protein in
the synovial fibroblasts [3]. Normal fibroblasts, while
having the capability to make TNF mRNA, block the trans-
lation process [4,5]. This is expected as fibroblasts are
found closely associated with extracellular matrix and the
catabolic activity of this cytokine would be extremely detri-
mental in this environment. Thus, while the huTNF trans-
genic mouse has proved to be very useful in
understanding TNF physiology and/or pathology, it is not a
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Abstract
In recent years, the effectiveness of anti-TNF therapy in treating rheumatoid arthritis (RA) has become
apparent. While trials of IL-1 receptor antagonist in RA have been encouraging, it clearly is more
difficult to target two molecules (IL-1 a and b) than one (TNF-a). In his review article, Professor Wim
van den Berg argues that both TNF-a and IL-1 must be blocked in RA and that although TNF is clearly
a potent inflammatory molecule, the dominant cytokine in the subsequent degradation of the joint
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and suggests explanations of why TNF-a is a pivotal cytokine in this disease.
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model for the human disease, not least because of the
aberrant nature of cells expressing TNF protein. However,
limitations apart, it is of interest that in these huTNF trans-
genic mice, a neutralizing monoclonal antibody to the
murine type I IL-1 receptor completely prevented the
development of arthritis, suggesting that IL-1 acts down-
stream of TNF in the pathogenesis of chronic arthritis [6].
The efficacy of this treatment may well be influenced by
the lytic nature of this antibody, as it is also effective in col-
lagen-induced arthritis [7].
The potent chondrogenic effects of IL-1 are well recog-
nised, and it is clear that IL-1 activates chondrocytes and
fibroblasts more potently than TNF does, a difference that
may reflect the relative abundance of IL-1 receptors on
these cells. In contrast, on monocytes and, indeed, more-
differentiated macrophages, TNF is a much more potent
activator than IL-1. Clearly, this difference reflects receptor
distribution, as monocytes have very few IL-1 receptors [8]
but relatively abundant p55 and p75 TNF receptors. The
pathogenicity of a molecule is thus determined by its
ability to activate a wide range of cells and to induce
several other proinflammatory molecules, which together
orchestrate the pathological process. This hypothesis in
relation to TNF has been demonstrated both in animal
models [9] and, more importantly, in human patients with
RA after anti-TNF antibody therapy (reviewed [10]). Thus
the cytokine/chemokine cascade is downregulated [11,12],
endothelium is deactivated [13,14], matrix metallopro-
teinases are reduced [15], and formation of new blood
vessels (angiogenesis) is also affected [16].
As the gene for TNF is transcribed and translated rapidly
(faster than that for IL-1), it probably occupies a higher
hierarchical position under conditions of cellular stress.
The development of sepsis in baboons given a bolus of
LPS is characterised by the sequential appearance of
TNF, IL-1, and IL-6 in the blood [17,18]. Moreover the
development of sepsis in these animals is blocked with
anti-TNF antibody, which also abrogates the serum rise in
IL-1 and IL-6. These findings are consistent with the
pivotal role of TNF in RA that our group proposed in 1989
[19]. More recently, a paper published by Ulfgren and col-
leagues, using a modified immunohistochemical method,
showed that, after TNF-blocking, synovial synthesis of
both IL-1 and TNF was diminished [20]. Clearly, immuno-
histology is a limited technique, and in that study the
number of patients was small and the cytokine profile het-
erogeneous, but the finding does further indicate the
importance of TNF in the cytokine cascade in RA.
Are arguments about TNF versus IL-1 relevant? While IL-1
is a very potent proinflammatory cytokine, the real thera-
peutic problem rests with the requirement to neutralise
both IL-1a and IL-1b in arthritic disease. In the setting of
diseased tissue, the normally cell-bound form of IL-1
(IL-1a) is found in abundance as a soluble molecule [21].
Interleukin-1 receptor antagonist (IL-1ra) is a very efficient
antagonist, but virtually all of the IL-1 receptors on a cell
must be blocked to abrogate signalling [22]. Secondly, it
is not clear why a substantial amount of IL-1ra remains
intracellular. Thus, although the trials of recombinant IL-1ra
in human RA look encouraging, the lack of a dose–
response effect is of concern [23]. The efficacy of the anti-
TNF modalities, particularly those with an IgG1 backbone,
may contribute to the better pharmokinetics of these
drugs than of IL-1ra. Alternatively, a different approach
using IL-1ra, such as gene therapy, may prove to be more
effective [24].
Does anti-TNF therapy prevent damage to cartilage and
bone? In his article, van den Berg hinted that it does not.
However, the publication of two full-length papers about
two anti-TNF agents, infliximab and etanercept, has now
made it very clear that anti-TNF treatment does indeed
slow down or prevent joint damage in human RA [25,26].
What is particularly remarkable about the infliximab study
was the observation that infliximab not only protected
intact cartilage but also halted/reversed ongoing erosions.
Furthermore, the group that did not respond clinically (as
assessed by the criteria of the American College of
Rheumatology) showed as much joint protection as the
responders. In the case of infliximab trials, further investi-
gation is needed to clarify how concomitant administration
of weekly doses of methotrexate contributes to these clini-
cal endpoints. However, these observations raise the real
possibility that the proportion of RA patients that respond
to anti-TNF therapy, at least as regards joint destruction, is
actually much higher than expected from the observed
reduction of symptoms and signs.
From the clinical trials described above, it is now clear that
proinflammatory cytokines are good targets in RA disease.
Furthermore, the mechanism of anti-TNF therapy has been
extensively studied in the infliximab studies and it its effec-
tiveness is clearly due to its ability to deactivate endothe-
lium, reduce the cytokine cascade, reduce the production
of matrix metalloproteinase, and prevent erosion. If block-
ing IL-1 results in a chondroprotective/ bone protective
modality alone, this may not be enough. A good therapy in
chronic inflammatory disease must achieve several objec-
tives, including the amelioration of signs and symptoms of
disease and the abrogation of joint destruction, and must
also be safe. However, because RA is a chronic disease, a
good therapy would also be one in which the cycle of
chronicity was broken. It is unclear at present whether the
anti-TNF or IL-1 antagonism therapies modulate the
chronicity of the disease. Therefore, there is still ample
room for modulation and improvement of these therapies,
and in particular it is important to targeting the mecha-
nism(s) leading to the disregulated production of these
proinflammatory mediators in inflamed tissue.References
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